Successful treatment of refractory palmoplantar pustulosis by upadacitinib: report of 28 patients

Abstract

Upadacitinib could be an additional safe and effective treatment for treating refractory palmoplantar pustulosis with a potential benefit on patients' quality of life. Further studies are needed to assess its short-and long-term efficacy and safety in larger sample sizes in randomized double-blind controlled trials.